BioInvent International

BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy. The company is advancing its clinical programs with a strategic focus on its lead assets, BI-1206 and BI-1808, which show promise in treating liquid and solid cancers. BioInvent collaborates with pharmaceutical companies and academic institutions to enhance its research capabilities and expand its clinical pipeline. The company is headquartered in Sweden and operates globally, leveraging partnerships to drive innovation and value creation in oncology treatments.

124

5.67

5.44

— BioInvent International
%
Immuno-oncology Therapies50% Includes BI-1206 and BI-1808 for cancer treatment
Oncolytic Viruses20% Includes BT-001 developed with Transgene
Outlicensed Projects15% Projects licensed to other companies for development
Antibody Production15% Production of antibodies for clinical studies

BioInvent's customer base includes pharmaceutical companies and academic institutions engaged in oncology research and...

  • Pharmaceutical Companiesprimary

    Buy novel cancer therapies and collaborate on clinical assets

  • Academic Institutionssecondary

    Collaborate on research and provide scientific expertise

  • Outlicensing Partnersemerging

    Engage in projects with potential for milestone payments

BioInvent is headquartered in Sweden and operates globally, with significant collaborations in Europe and the USA...

  • •Headquartered in Sweden with global operations
  • •Collaborations in Europe and the USA with pharmaceutical giants
  • •Antibody production facilities located in Sweden
  • •Strategic presence in key oncology research markets

BioInvent's strategic focus is on accelerating the development of its lead clinical programs, BI-1206 and BI-1808, to...

01
Accelerate Lead Programsmedium-term

To maximize therapeutic impact and shareholder value

02
Strategic Collaborationslong-term

To enhance value creation and expand clinical pipeline

BioInvent faces several risks, including the inherent uncertainties of clinical trials and regulatory approvals...

critical

Clinical Trial Uncertainty

Potential delays or failures in trials

Materiality
high
high

Partnership Dependency

Reliance on partner performance for project success

Materiality
medium
medium

Revenue Fluctuation

Variability in income from outlicensed projects

Materiality
medium
Revenue Recognition
medium
Milestone Payments
high

BioArctic

BIOA-B.ST · Health Care

BIOVIE INC.

BIVI · Pharmaceutical Preparations

ArriVent BioPharma, Inc.

AVBP · Pharmaceutical Preparations

Cantargia

CANTA.ST · Health Care

Roivant Sciences Ltd.

ROIV · Pharmaceutical Preparations

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

: 11/08/2026